Julia Tsai
Ovid Therapeutics

Julia is the Vice President of Clinical Development at Ovid Therapeutics where she is responsible for clinical development activities for soticlestat and any new epilepsy related compound. She has over 16 years of industry experience and had been responsible for strategic and operational activities and participated in regulatory interactions for several general and rare epilepsy programs including the first pivotal study in CDKL5 Deficiency Disorder. Before joining Ovid, she was the Vice President of Clinical Development at Marinus Pharmaceuticals where she led the epilepsy programs and responsible for clinical development and clinical operations and oversaw preclinical/nonclinical activities.